ReviewCurrent rheumatology reports2013
Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease.BMJ open · 2018Pooled it
- Epidemiology of idiopathic inflammatory myopathies: a population-based cohort in England, 2002-2021.RMD open · 2026Article
- Defining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC).Systematic reviews · 2026Article
- Clinical and Serological Characteristics of Idiopathic Inflammatory Myopathies According to the Presence of Interstitial Lung Disease and Initial Evaluating Medical Specialty: A Single-Center Experience.Journal of personalized medicine · 2026Article
- Severe laryngeal oedema unexpectedly observed during bronchoscopy in a patient with anti-MDA5-positive dermatomyositis.BMJ case reports · 2025Article
- Pirfenidone alleviates interstitial lung disease in mice by inhibiting neutrophil extracellular trap formation and NLRP3 inflammasome activation.Clinical and experimental immunology · 2025Article
- Predictors of relapse of polymyositis/dermatomyositis associated interstitial lung disease.Journal of thoracic disease · 2024Article
- Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa.African journal of thoracic and critical care medicine · 2024Article
- A Narrative Review of Acthar Gel for the Treatment of Myositis.Rheumatology and therapy · 2023Review
- Anti-signal recognition particle positive necrotizing myopathy-sjogren's syndrome overlap syndrome: a descriptive study on clinical and myopathology features.BMC musculoskeletal disorders · 2023Article
- Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.Frontiers in immunology · 2023Article
- Inflammatory myopathies: an update for neurologists.Arquivos de neuro-psiquiatria · 2022Review
- Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.European radiology · 2022Article
- Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease.Frontiers in immunology · 2022Article
- A New Predictive Model for the Prognosis of MDA5Frontiers in medicine · 2022Article
- Validation of methods to identify people with idiopathic inflammatory myopathies using hospital episode statistics.Rheumatology advances in practice · 2022Article
- Clinical features and outcomes of patients with myositis associated-interstitial lung disease.Frontiers in medicine · 2022Article
- The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Dermatomyositis autoantibodies: how can we maximize utility?Annals of translational medicine · 2021Review
- Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.Drugs in context · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) is a very important complication of the idiopathic inflammatory myositides (IIM), with a prevalence of approximately 40 %. Characteristic HRCT changes, most commonly NSIP, together with a restrictive ventilatory defect and an associated decline in DLco support the presence of ILD. The strongest risk factors are the presence of the anti-amino-acyl-tRNA synthetases (ARS) and anti-MDA-5 antibodies, but a raised index of suspicion for ILD should also apply to IIM patients of black ethnicity. Overall, the prognosis of ILD in IIM is good; between 50 and 66 % of cases have a stable disease course over a substantial period of time. The remaining proportion will show signs of worsening lung disease within 12 months of diagnosis. Whereas ARS antibodies and black ethnicity have no influence on ILD prognosis, detection of the anti-MDA-5 antibody carries a poor ILD outcome, in which hyperferritinaemia appears to be an important diagnostic and prognostic feature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.